© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 18, 2022
Therapeutic candidate Sparsentan could expand treatment options for 2 rare kidney diseases. Dr. Jula Inrig expands on the potential for the FSGs patient population.
November 16, 2022
Dr. Jula Inrig explains the mechanism of action for the Dual Endothelin Angiotensin Receptor Antagonist (DEARA) investigational candidate Sparsentan, for rare kidney diseases.
November 07, 2022
Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.
November 05, 2022
The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.
Low sodium intake is considered less than 2.3 grams per day.
Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.
In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.
November 04, 2022
Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.
There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.
In a late-breaking abstract, investigators observed a 28% reduction in kidney disease progression or cardiovascular deaths compared to placebo.
High Relapse Rate After Discontinuing Antiviral Therapy for HBV Patients With Cirrhosis
Insomnia, Hypersomnia Identified as Symptoms of Long COVID Syndrome
Study Evaluates Insomnia and Suicidality Among Healthcare Workers During COVID-19 Pandemic